Candid Therapeutics, which is repositioning two antibodies for autoimmune indications, will be led by Ken Song who was previously CEO of RayzeBio and oversaw its $4.1 billion acquisition by Bristol Myers Squibb.
Despite the disappointing late-stage results in non-small cell lung cancer, Jefferies analyst Stephen Barker contends the likelihood of FDA approval “remains high” for the experimental antibody-drug conjugate, though the regulator is now more likely to convene an advisory committee.
One in seven Americans have signed up for health insurance coverage through Affordable Care Act marketplaces since their 2014 launch, according to data released on Tuesday by the U.S. Department of the Treasury.
The U.S. House of Representatives on Monday overwhelmingly passed the bipartisan bill, which targets WuXi AppTec, WuXi Biologics and other Chinese biotech companies as potential national security risks.
Avalere Health has appointed Corrina Safeio as its new president, global marketing and EVP, corporate communications.
AbbVie has sued cancer treatment maker BeiGene in Chicago federal court, accusing it of stealing trade secrets to develop a competing cancer-fighting therapy after hiring away a former longtime senior AbbVie scientist.